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INTRODUCTION
A major problem encountered in radio-and chemotherapy of solid tumors is the severe side effects caused by their normal tissue toxicity at the therapeutic doses. It may be possible to get effective tumor control with reduced side effects by using agents that can increase the tumor sensitivity to these treatments. Withaferin A (4β 27-dihydroxy-1-oxo 5β, 6β, epoxy witha 2-24 dienolide, Fig. 1 ), a steroidal lactone, is found in the leaves and roots of the Indian medicinal plant, Withania somnifera [1] [2] [3] . This compound has been demonstrated to sensitize mouse Ehrlich ascites carcinoma in vivo 3, 4) and Chinese hamster V79 cells in vitro 5) . Studies on a transplanted mouse fibrosarcoma 6) and melanoma 7) have shown that withaferin A has a weak tumor growth inhibitory effect on its own, but exhibited significant radiosensitizing activity when given before radiotherapy. The applicability of the drug as a radiosensitizer in clinical cancer therapy depends on its tolerance after repeated administration with fractionated radiotherapy. Therefore, the present study was undertaken to determine the effect of withaferin A in combination with acute and fractionated radiotherapy and hyperthermia on two mouse tumors of differing radiosensitivity, i.e. a melanoma and a fibrosarcoma.
MATERIALS AND METHODS

Tumor
B16F1 mouse melanoma (M) was originally procured from Cancer Research Institute, Mumbai, India, and propagated by serial transplantation on the dorsal skin of adult C57BL mice of either sex. Fibrosarcoma (FS) 
Drug
Withania somnifera root powder was a gift from Vaipa Pharmaceuticals Ltd., India. Ethanolic extract of the root powder was prepared by the method of Suffness and Douros 8) and withaferin A (WA) was isolated by the method of Subramanian and Sethi 2) with slight modifications 9) . Withaferin A was dissolved in a few drops of ethanol and a homogeneous suspension was made with 0.5% carboxy methyl cellulose (CMC) in phosphate buffered saline. Fresh solution was prepared before each experiment.
Irradiation (RT)
Animals were anaesthetized by intraperitoneal (i.p.) injection of 50 mg/kg of Ketamine (Themis, India) and 0.5 mg/mouse of diazepam (Ranbaxy, India). Local irradiation of the tumor was done from a 60 Co teletherapy source (Siemens, Germany, at the department of Radiotherapy, SSB Cancer Hospital and Research Centre, Manipal, India) at a dose rate of 1 Gy/min, in a field size of 4 × 4 cm.
Hyperthermia (HT)
Local hyperthermia was applied by immersing the tumors in a constant temperature circulating water bath (Julabo, Germany). The irradiation and hyperthermia procedures for solid tumors have been described earlier 10) .
Experimental design
The following experiments were carried out: WA, RT and HT (single dose): WA, 40 mg/kg, was injected i.p. 1 h before local exposure of tumors to 30 Gy gamma radiation, immediately followed by local HT (43°C, 30 min). The time of WA injection was selected from a previous study using different time intervals from 12h before to 2h after irradiation in which injection 1h before irradiation produced the maximum effect 7) . Single modality (WA, RT or HT) and bimodality (WA+RT, WA+HT or RT+HT) treatments were also given in different sets of tumor bearing animals, for comparison. The dose of WA was selected on the basis of dose-response studies, reported earlier 6, 7) . In each group 10-25 animals were used.
WA, RT and HT (RT dose fractionation): Radiation, 50 Gy, was given as a single dose or in fractions of 10 Gy daily for 5 consecutive days. Injection of 40 mg/kg for more than 3 days produced toxic symptoms like lethargy, reduced food intake and weight loss. Therefore, 30 mg/kg b.wt. WA was injected i.p., alone or followed by local irradiation (10 Gy), for five consecutive days. Two other groups of mice were given local HT immediately after the first fraction of radiation or WA+ radiation. For the bi-and tri-modality treatments, 10-30 animals were used in each group.
Parameters: The animals were observed for 120 days and the following parameters were studied: Volume doubling time (VDT): time (in days) required for the tumor to attain double the treatment volume; Growth delay (GD): the difference in time (days) between the treated and the untreated tumors to reach 5 times the treatment volume; Complete response (CR): complete regression with no regrowth at the primary site during 120 days of observation;
Partial response (PR): a regression of 50% or more from the treatment volume; Total response (TR): sum of CR and PR.
VDT and GD were calculated in all tumors that do not show complete response.
All studies were conducted according to the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India.
Statistical analysis
Statistical comparison of the different treatment groups was done by one-way ANOVA test. The interaction of different agents (drug, radiation and hyperthermia), when used in combination, was assessed by the S-factor (index of synergy) 11) .
RESULTS
WA, RT and HT (single dose)
Melanoma: None of the single modalities produced any complete response. RT (30 Gy) and HT individually produced 30% and 8% partial responses respectively, but WA alone did not induce any PR. Withaferin A or local hyperthermia, individually, produced almost similar GD (4.1 and 4.3 days, respectively) and VDT (5.5 and 5.67 days, respectively), while RT (30 Gy) alone resulted in VDT and GD of 16 days (Table 1) . When WA was injected 1 h before RT in a bimodality regimen, no complete regression was obtained. But the PR% increased synergistically, while the increase in VDT and GD was additive. When RT was followed by HT, there was a marked increase in tumor response with about 23% CR, 36% PR and subadditive increases in VDT and GD of the non-CR tumors. Combination of WA with HT resulted in a subadditive increase in VDT and additive increase in GD, with 25% PR but no CR; the response to this combination was inferior to that to RT alone. Combination of all the three modalities resulted in a synergistic increase in both CR (37%) and PR (47%) (total response = 84%) and additive increase in the VDT and GD of non-CR tumors (Table 1) .
Fibrosarcoma: Unlike in melanoma, 40 mg/kg of WA alone produced 40% PR, but no CR, and also increased the VDT and GD. Among the single modalities, RT produced the maximum tumor response, giving 33% CR and 33% PR. Combination of WA with HT resulted in a similar CR, VDT and GD as that after RT alone. While RT + HT gave a better tumor control than WA + HT, the most effective bimodality treatment was WA + RT, which gave 55% CR and 45% PR and significantly (p < 0.001) enhanced the VDT and GD above that of the other bimodality and all single modality treatments. Addition of HT to this regimen further enhanced the CR (64%), but did not have any significant additional effect on the growth rate of the uncured tumors (Table 2) .
WA, RT and HT (RT dose fractionation)
Melanoma: WA injection at 40mg/kg was not tolerated when repeated daily for more than 3 days. But, daily injection of 30 mg/kg of WA, i.p., for 5 days, given alone or with radiation, did not produce any toxic side effects in the mice. A total dose of 150 mg/kg (30 mg/kg × 5) of WA resulted in 11.76% CR and 23.5% PR and also increased the VDT and GD (Table 3) above those of the single dose of 40 mg/kg WA (Table 1) . While 50 Gy of radiation given as an acute dose could not produce any CR, the same total dose administered in a fractionated regimen (10 Gy × 5) increased the tumor response, resulting in 25% CR and 35% PR (TR = 60%). The VDT and GD of the non-CR tumors did not differ significantly from that obtained with the acute irradiation (50 Gy). WA combination with acute dose of 50 Gy was not tolerated by the mice and also produced some skin reactions. When 30 mg/kg WA was given before each fraction of 10 Gy, there was a synergistic increase in CR (61%) and resulted in 94% TR. The VDT and GD also increased significantly above that of the single modality treatments and this increase was subadditive. HT treatment after the first WA + RT of the fractionated regimen further enhanced the tumor response to a TR of 100%, with 68% CR. The VDT and GD of the PR tumors also increased significantly above those seen after all bimodality treatments (p < 0.001) ( Table 3) .
Fibrosarcoma: Daily administration of WA for 5 days produced a similar CR and PR as that after heat alone treatment, but a slightly higher VDT and GD than the latter. Radiation (50 Gy) produced an almost similar tumor cure effect when given as an acute dose and when administered in 5 fractions, and the effect was significantly higher than that of HT or WA. All bimodality treatments markedly increased the CR and GD compared to the corresponding single modalities, but the combination of WA + HT was less effective than RT alone and the other bimodality treatments. Five doses of WA + 10 Gy gave similar VDT and GD as those obtained with (10 Gy × 5) + HT, while the drug + RT gave a higher CR% than the RT + HT combination. When one heat treatment was added after the first dose of the (WA+RT) × 5 regimen, there was a synergistic increase in the CR%; VDT and GD were also considerably increased in comparison to the bimodality treatments (Table 4) .
DISCUSSION
In this study we have used two transplantable mouse tumors with notable difference in radiosensitivity, a radioresponsive fibrosarcoma and a radioresistant melanoma. Preliminary studies done on melanoma and fibrosarcoma demonstrated that local exposure of the tumors to 10 Gy-60 Gy produced a dose dependent increase in tumor growth delay up to 40 Gy (fibrosarcoma) and 50 Gy (melanoma), above which the increase in tumor response was not pronounced 6, 7, 12) . Treatment with 10-40 mg/kg of WA before an acute dose RT has been found to enhance the effect in a dose dependent manner and WA (40 mg/kg) + RT (30 Gy) produced the best results, in terms of tumor growth delay, in both fibrosarcoma 6) and melanoma 7) . A comparison of data in tables 1 and 2, in the present study, shows that melanoma responded poorly to all single modalities as well as WA + HT treatments. On the contrary, the fibrosarcoma showed a moderate response to HT and WA + HT and a higher response (TR = 90-100%) to HT, RT and the other bimodalities and trimodality treatment. These results indicate the relative resistance to treatment of the melanoma. This is in agreement with our earlier findings on B16F1 melanoma 13) and on human melanoma xenografts 14) . In the present study, the radioresponse of the melanoma was significantly increased by fractionated radiotherapy, while dose fractionation had very little effect on the fibrosarcoma. This could be attributed to the higher fraction of hypoxic cells in melanoma than in the fibrosarcoma. Reoxygenation may occur between two fractions, which could increase the sensitivity of the tumors to fractionated irradiation 15) . Such an effect could have resulted in the higher tumor control observed in the present study for the melanoma receiving fractionated radiotherapy. The occurrence of high hypoxic fractions in rodent and human melanoma has been reported earlier 16, 17) . The presence of hypoxic cells in melanoma may also explain the finding that, when used as single doses, RT+HT was more effective (CR 22%) than WA+RT, whereas the reverse was true in fibrosarcoma. Hypoxic cells have been shown to be more sensitive to hyperthermia compared to oxy- Table 3 . Response of B16F1 melanoma to WA treatment before fractionated RT for 5 days, with/without HT after the first dose.
Treatment groups
No. of animals Table 1 .
genated tumor cells 18) . We have also observed, in an earlier study, that hyperthermia treatment under acute ischemia (clamping) caused a drastic increase in cell death by apoptosis in the B16F1 mouse melanoma 13) . Although WA injection before each fraction of RT produced a significant increase in the response of melanoma, the sensitizing effect of WA does not seem to be specific to hypoxic cells, as fibrosarcoma gave a better response to WA+RT (CR 55%) than to RT+HT (CR 40%). This is further evidenced in the finding that a single treatment with 40 mg/kg of WA before RT from 10 Gy to 40 Gy produced a higher response in fibrosarcoma than in melanoma, suggesting its sensitizing effect on the oxygenated cells 12) . Lack of hypoxic cell specificity of WA has also been indicated in our earlier studies, where WA at subtoxic doses significantly enhanced the radiosensitivity of exponentially growing Ehrlich ascites carcinoma in vivo 4) and Chinese hamster V79 cells in vitro 5) . The trimodality treatment (WA + RT + HT) gave a much higher tumor response compared to all other treatments in both melanoma and fibrosarcoma, both in single as well as in multiple dose treatments. Similarly, we had observed very significant increase in the response of a mouse sarcoma with trimodality therapy using single doses of the cancer chemotherapeutic drugs bleomycin 10) and cisplatin 19) with local irradiation and hyperthermia. These and other studies 20, 21) have shown that the normal tissue toxicity of chemotherapeutic agents can be reduced without compromising their tumor cure effect by combining the treatment with radiation and hyperthermia. The present finding that daily administration of WA for 5 days could produce more than 10% CR even in the resistant tumor melanoma demonstrates its potential as a cancer therapeutic agent. But this compound appears to be more promising as a radiosensitizer when used with fractionated radiotherapy. Our results demonstrate that WA and HT, in combination, can significantly enhance the therapeutic effect of radiation on tumors with differing radiosensitivities. Use of WA before every fraction of radiotherapy with one dose of hyperthermia per week may be an efficient approach for the control of radioresistant tumors like melanoma.
One significant finding of the present study is that a total dose of 150 mg/kg, which is about two times the LD 50 (~80 mg/kg 9) ) of WA, was tolerated by the mice when given in daily fractions of 30 mg/kg with RT. However, in another experiment we have observed that daily injection of 16 mg/kg of WA, which is 1/5th the LD 50, for 30 days reduced the body weight and also resulted in significant changes in serum enzymes, although no gross histopathological changes in the major organs were noticed 12) . For application with fractionated radiotherapy of cancer the daily dose of WA may have to be reduced. Moreover, the radiation dose fractions used in the present study are much higher than those used in the standard clinical practice. Further studies with daily administration of WA with radiation schedules in the clinically relevant dose range need to be done in order to determine a safe dose regimen for clinical trials.
CONCLUSION
Withaferin A seems to be a promising radiosensitizer for use with radiotherapy of radioresistant solid tumors. However, more work is needed to establish a safe drug dose for administration with conventional radiation dose fractions in humans.
